Global Allergy & Airways Patient Platform

🧬 HCPs: Explore new CME opportunities and publications. 🤝 Patients: Find out how you can participate in global research on bronchiectasis, asthma, hives, and more. 🔗 Subscribe to our newsletter: gaapp.org/sign-up-for-th…

We’re in Denver on 26 March for the 1st North American Alliance Meeting! We’re uniting to advocate for the 78M+ people in NA living with chronic respiratory & skin conditions. Get the latest on our regional advocacy: gaapp.org/sign-up-for-th…

Call for Abstracts for Early Career Researchers: share your work at ICAN 2026 (5 September, Barcelona). Join a collaborative community advancing respiratory research — from immune mechanisms and treatment response to AI, imaging, and novel therapies. Connect with peers and global experts across academia, industry, NIH, ERS, and more. Only 50 abstracts will be selected. ✈️ Selected abstracts will receive travel support + accommodation 📅 Deadline: 15 April, 2026 🔗 ican.gaapp.org

New Ph3 data for lebrikizumab-lbkz shows 63% of pediatric patients (6mo+) achieved EASI-75. 🔗 investor.lilly.com/news-releases/…

Join GAAPP President Tonya Winders & experts for a new @Medscape CME workshop on overcoming adherence barriers in COPD & asthma. Free for global HCPs: ms.spr.ly/6008Q8XJj #CME #RespiratoryHealth #HCP

In celebration of International Women’s Day, join us for the next #GAAPPAcademy webinar TOMORROW! 9 global experts share their journey with leadership and community impact as they discuss “The Role of Women in Patient Advocacy”. 🗓 TOMORROW, 9 March 2026 🕒 15:00 CET 🔗 Register: us06web.zoom.us/webinar/regist…

Oral steroids are often a go-to for severe asthma, but at what cost? In EP 23 of Passion for Patients, Tonya Winders & Hilary Hodge discuss the "double impact" of asthma & adrenal crisis. It's time for Steroid Stewardship. Watch now: youtube.com/watch?v=etaYqO…

GAAPP is heading to São Paulo (in person!) to support our member organization, Instituto Unidos pela Vida, at the Conecta Saúde Forum 2026. This event dives deep into Health Technology Assessment (HTA), the role of AI in healthcare, and overcoming logistical barriers to treatment for rare and respiratory diseases in places like Brazil. Whether you are across the ocean or around the corner, you can join the conversation! 📅 Date: 11 March, 2026 🌍 Translation available to English and Spanish. 🔗 Register for online attendance: eventos.congresse.me/forumconecta26 . . #SupportedbyGAAPP #ForumConecta26 #RareDiseases #RespiratoryDiseases #HTA #PatientAdvocacy #PublicPolicy

In celebration of International Women’s Day, join us for the next #GAAPPAcademy webinar! 9 global experts share their journey with leadership and community impact as they discuss “The Role of Women in Patient Advocacy”. 🗓 9 March 2026 🕒 15:00 CET 🔗 Register: us06web.zoom.us/webinar/regist…

@EMA_News's CHMP has issued a positive opinion recommending the approval of dupilumab for children aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite antihistamine treatment. 🔗 sanofi.com/en/media-room/…

New research from GAAPP’s Tonya Winders & PIPA’s Marilyn Urrutia-Pereira! "Nature prescriptions" for #asthma & COPD can improve lung function, reduce inflammation & boost well-being. Read the full study here: worldallergyorganizationjournal.org/action/showPdf…

Panama is taking a bold stand for #LungHealth! Our members at @fundacion_panama_respira are pushing for a national Respiratory Health Law based on the WHA Resolution. Is your government reacting yet? Take action here: gaapp.org/lunghealthreso…

Over 300M people worldwide live with a rare disease—including 6.8M fighting rare skin conditions. Today, GAAPP joins @GlobalSkin to demand better research, recognition, and resources for the 800+ rare skin diseases affecting patients daily. #RareDiseaseDay #RareSkin

Repost from @rarediseasedayofficial: Today we stand with the 300 million people living with a rare disease. We are united with their families, friends, caregivers, advocates, and the medical professionals, researchers and organisations that working tirelessly to build a more equitable future for our community. #RareDiseaseDay

In celebration of International Women’s Day, join us for the next #GAAPPAcademy webinar! 9 global experts share their journey with leadership and community impact as they discuss “The Role of Women in Patient Advocacy”. 🗓 9 March 2026 🕒 15:00 CET 🔗 Register: us06web.zoom.us/webinar/regist…

Our Asia Pacific Regional Alliance leadership met with 4 local member orgs in Nepal to develop a new project: COPD screening + chest physical therapy for underserved communities. Local expertise leading the way for better lung health. Stay tuned for more updates as we roll out this initiative! #SupportedbyGAAPP #COPD #PublicHealth #Nepal #RespiratoryCare

COPD is the 3rd leading cause of death worldwide. In Ghana, it's a top 10 killer. Prince Osei Poku, from our member org Asthma Ghana and a @COPDFoundation State Captain, calls for a National Action Plan to implement the Lung Health Resolution. We need policy change NOW to save lives. 🇬🇭 Take action: gaapp.org/lunghealthreso…

Our Brazilian member @abraf.ong is transforming the landscape for lung health through policy change, direct action, and data-driven insights. Their recent survey found that 50% of COPD patients under specialist care still required ER visits last year—proving the urgent need for the better care pathways and early diagnosis that this org champions. Help people with lung conditions in Brazil thrive like Iara! Donate today to support ABRAF's next initiative: paypal.com/paypalme/gaapp…

Our team, including Ruth Tal-Singer, Kristen Willard, & Stephanie Williams, alongside experts from @JohnsHopkins and @UMmedschool, just published a study on Vaccine. 60% of the 3,000+ US adults with chronic conditions would take an antiviral for flu or COVID-19 if offered by a prescriber, yet many patients still perceive they "don't need" them until a hospitalization occurs. 🔗 sciencedirect.com/science/articl… #ScienceNews

For the 29M people worldwide living with chronic inducible urticaria, many find that standard antihistamines just aren't enough. The good news is that a new Phase III clinical trial has shown positive results for a potential oral treatment designed to block the pathway that releases histamine. The results showed that many participants achieved a "complete response" (relief from symptoms) compared to those on a placebo. 🔗 ow.ly/K5io50YiiNU